Rock Soffer Buys 31,915 Shares of Longeveron Inc. (NASDAQ:LGVN) Stock

Longeveron Inc. (NASDAQ:LGVN) Director Rock Soffer purchased 31,915 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average cost of $2.35 per share, with a total value of $75,000.25. Following the purchase, the director now directly owns 208,534 shares in the company, valued at $490,054.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Longeveron Trading Down 16.3 %

NASDAQ:LGVN opened at $1.69 on Friday. The company has a market capitalization of $4.25 million, a PE ratio of -0.17 and a beta of 0.21. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.21. Longeveron Inc. has a 52-week low of $1.62 and a 52-week high of $44.00. The stock has a fifty day simple moving average of $4.32 and a 200-day simple moving average of $12.35.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($2.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.10) by ($0.40). The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.21 million. Longeveron had a negative return on equity of 209.14% and a negative net margin of 3,020.17%. On average, equities research analysts expect that Longeveron Inc. will post -8.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LGVN. Citigroup Inc. acquired a new position in shares of Longeveron during the 1st quarter worth $1,004,000. Vanguard Group Inc. raised its stake in Longeveron by 17.5% in the 1st quarter. Vanguard Group Inc. now owns 115,865 shares of the company’s stock valued at $1,599,000 after purchasing an additional 17,229 shares during the last quarter. Gamco Investors INC. ET AL acquired a new position in Longeveron in the 1st quarter valued at about $449,000. Northern Trust Corp acquired a new position in Longeveron in the 2nd quarter valued at about $63,000. Finally, State Street Corp acquired a new position in Longeveron in the 2nd quarter valued at about $88,000. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.